|
< Back to Newsroom
|
MultiCell
Technologies Receives Two International Trademark Protections
LINCOLN, R.I., May 3 /PRNewswire-FirstCall/ --
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET - News), has received International
Trademark Registration No. 846 389 for the name "Biofactories".
The Company's patented hepatocytes are termed Biofactories because of their
ability to naturally express or produce therapeutic proteins. The Company's
immortalized non-tumorigenic adult human hepatocytes are also valuable for
use in drug discovery screening applications.
MultiCell Technologies
has also been granted International Trademark Registration No. 902 524 for
"MultiCell Therapeutics", a name which may be used for one or
more of the company's developmental therapeutic products.
MultiCell is a
pharmaceutical company developing therapeutics based on immune system
modulation, toll receptor techniques, stem cells and other patented drug
development techniques. MultiCell's therapeutic pipeline includes potential
therapeutics for the treatment of chronic fatigue in MS patients, for
treatment of relapsing-remitting MS, for juvenile diabetes, viral
infections, influenzas and some cancers.
MultiCell Technologies,
Inc. has offices and labs in Lincoln, RI and San Diego, CA. For more information about
MultiCell Technologies, please visit http://www.multicelltech.com.
To receive future news releases by email, email MCETinvestor@muticelltech.com.
Caution Regarding
Forward-Looking Statements
Any statements in this
press release about MultiCell's expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and
are forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"). These statements are
often, but not always, made through the use of words or phrases such as
"believe," "will," "expect,"
"anticipate," "estimate," "intend,"
"plan," "forecast," "could," and
"would." Examples of such forward looking statements include
statements regarding the timing, design, scope, and anticipated results of
our clinical development programs. MultiCell bases these forward- looking
statements on current expectations about future events. They involve known
and unknown risks, uncertainties and assumptions that may cause actual
results, levels of activity, performance or achievements to differ
materially from those expressed or implied by any forward-looking
statement. Some of the risks, uncertainties and assumptions that could
cause actual results to differ materially from estimates or projections in
the forward-looking statement include, but are not limited to, the risk
that we might not achieve our anticipated clinical development milestones,
receive regulatory approval, or successfully commercialize our products as
expected, the market for our products will not grow as expected, and the
risk that our products will not achieve expectations. For additional
information about risks and uncertainties MultiCell faces, see documents
MultiCell files with the SEC, including MultiCell's report on Form 10-KSB
for the fiscal year ended November 30, 2006, and all our quarterly and other
periodic SEC filings. MultiCell claims the protection of the safe harbor
for forward-looking statements under the Act and each assume no obligation
and expressly disclaim any duty to update any forward-looking statement to
reflect events or circumstances after the date of this news release or to
reflect the occurrence of subsequent events
Contact:
MultiCell Technologies, Inc.
Dr. Stephen Chang, 858.200.0598
MCETInvestor@MultiCelltech.com
Source: PR Newswire (Tuesday May 03, 9:00 am ET)
|
